Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
NCT07269210 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Solbinsiran
Study Locations (20)
California
- National Heart Institute — Beverly Hills
- Ark Clinical Research — Long Beach
- Catalina Research Institute, LLC — Montclair
- Valley Clinical Trials, Inc. — Northridge
Florida
- Northeast Research Institute - Downtown Office — Jacksonville
- Novera Clinical Research — Miami
- Inpatient Research Clinic — Miami Lakes
- Clinical Site Partners, LLC dba Flourish Research — Winter Park
Arizona
- Axsendo Clinical Research - Peak Heart & Vascular - Phoenix — Phoenix
- Synexus Clinical Research US, Inc./Orange Grove Family Practice — Tucson
New York
- Weill Cornell Medical College — New York
- Icahn School of Medicine at Mount Sinai — New York
Connecticut
- CMR of Greater New Haven, LLC — Hamden
Illinois
- Great Lakes Clinical Trials - Ravenswood — Chicago
Indiana
- Investigators Research Group — Brownsburg
Kentucky
- Saint Elizabeth Healthcare - Saint Elizabeth Covington Hospital — Covington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-12-08 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07269210
The ClinicalTrials.gov registry entry for NCT07269210 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 704 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07269210 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07269210 about?
NCT07269210 is a clinical study titled "A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia". The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
What is the current status of trial NCT07269210?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-12-08. Estimated completion is 2027-08.
What conditions does trial NCT07269210 study?
This clinical trial studies the following conditions: Severe Hypertriglyceridemia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07269210?
The interventions under investigation include: Placebo (DRUG), Solbinsiran (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07269210?
This trial is sponsored by Eli Lilly and Company, which has 704 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07269210 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.